AI in Antibody Discovery Market to Reach USD 3.16 Billion by 2034, Growing at 21.57% CAGR
核心洞察
The global AI in antibody discovery market was valued at USD 546.17 million in 2025 and is projected to reach USD 3,162.19 million by 2034, expanding at a CAGR of 21.57%.
North America dominated the market with a 43.72% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate with a CAGR of 23.26%.
Monoclonal antibodies (搜索) accounted for the largest antibody modality share at 54.41%, driven by established clinical pathways and abundant training datasets for AI model development.
The global market for artificial intelligence in antibody discovery reached a valuation of USD 546.17 million in 2025 and is on track to surpass USD 3.16 billion by 2034, reflecting a compound annual growth rate (CAGR) of 21.57% over the forecast period, according to a new report from Straits Research. The rapid expansion underscores the transformative role AI technologies are playing in accelerating therapeutic antibody development across oncology, autoimmune diseases, infectious diseases, and rare disease research.
North America commanded the largest regional share at 43.72% in 2025, with the United States alone accounting for USD 208.70 million in market value. The Asia Pacific region, while smaller in absolute terms, is projected to grow at the fastest pace with a CAGR of 23.26%, fueled by expanding biotechnology infrastructure and increasing R&D investments. Japan's AI in antibody discovery market was valued at USD 18.12 million in 2025 and is expected to reach USD 22.02 million in 2026.
Technology Landscape: Structure Prediction Leads, Generative AI Surges
Structure prediction emerged as the dominant technology segment in 2025, capturing a 32.12% market share. Its prominence stems from its critical role in accurately modeling antibody-antigen binding conformations, enabling rational molecular engineering and improving candidate selection prior to laboratory validation. High prediction accuracy reduces experimental iterations while supporting efficient therapeutic antibody optimization.
The generative AI and protein language models segment is poised for rapid expansion, with a projected CAGR of 22.33% during the forecast period. These technologies enable de novo antibody sequence generation, biological sequence learning, and continuous self-improving molecular prediction capabilities, significantly broadening therapeutic design possibilities.
Monoclonal Antibodies (搜索) Dominate Modality Segmentation
By antibody modality, monoclonal antibodies (搜索) held the largest market share at 54.41% in 2025. This dominance reflects their established clinical development pathways, abundant training datasets for AI model development, and widespread therapeutic applicability across multiple disease indications. Their extensive commercial success continues to encourage AI-assisted optimization and discovery activities.
The antibody-drug conjugate (ADC) segment is expected to register a CAGR of 22.76%, driven by increasing computational optimization of linker chemistry, payload conjugation sites, and tumor targeting specificity. AI accelerates complex ADC design by simultaneously optimizing multiple molecular characteristics for therapeutic efficacy.
Application and End-User Dynamics
Target identification and validation accounted for 29.68% of the market by application in 2025, reflecting AI-driven biomarker prioritization and efficient identification of disease-associated therapeutic targets. The lead optimization and engineering segment is forecast to grow at a CAGR of 22.50%, driven by computational affinity maturation, sequence liability prediction, and simultaneous optimization of stability and manufacturability.
Pharmaceutical companies represented the largest end-user segment with a 32.30% share in 2025, leveraging extensive biologic pipelines and strong capabilities for integrating computational discovery with clinical development. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are projected to grow at a CAGR of 22.85%, as these entities increasingly deploy AI-enabled antibody discovery within integrated R&D service offerings.
Competitive Landscape and Recent Developments
The competitive landscape is moderately fragmented, featuring AI-native biotechnology companies, computational drug discovery firms, and established pharmaceutical organizations. Key players include Absci, Adimab, Generate:Biomedicines, Insilico Medicine, ImmunoPrecise Antibodies, Schrödinger, BigHat Biosciences, Antiverse, LabGenius, Evotec, Harbour BioMed (搜索), and Genmab.
In September 2025, Absci announced a strategic collaboration with Oracle Cloud Infrastructure (搜索) and AMD (搜索) to accelerate generative AI-driven drug discovery. The following month, Absci and Almirall expanded their AI drug discovery collaboration by adding a second dermatology target after the successful delivery of AI-designed functional antibody candidates against the first target, highlighting the growing momentum behind AI-powered therapeutic development partnerships.